The central goal of the proposed research is to determine mechanisms by which viral infections lead to loss of tolerance (LOT) to oral antigen and induce celiac disease (CD) and to design strategies to prevent virus- induced LOT and CD onset. Viral infections are increasingly recognized as contributing factors in the pathogenesis of autoimmune inflammatory diseases. However, little is known about the biological features that enable a virus to provoke inflammatory tissue injury. CD is a T cell-mediated intestinal disorder with an autoimmune component characterized by an inflammatory anti-gluten immune response that occurs exclusively in gluten-exposed persons with HLA DQ2 or DQ8 alleles. Approximately 45% of the U.S. population expresses DQ2 or DQ8, yet only 1% of the population develops the disease, indicating that additional factors contribute to disease induction. Reoviruses are human dsRNA viruses recently linked to CD. These viruses infect the murine intestine and can be genetically manipulated to identify viral determinants of autoimmune host responses. We discovered that reovirus strain T1L abrogates tolerance to dietary antigens including gluten using a pathway dependent on IRF1, whereas strain T3D-RV does not. Induction of protective immunity to T1L occurs by a mechanism distinct from that required for immunopathology. We propose to enhance an understanding of how viruses influence the development of autoimmune inflammatory disorders and prevent CD by identifying virus and host factors that influence LOT to dietary antigen and defining strategies to block virus-induced LOT and CD development. To achieve this goal, we have designed three well-integrated specific aims.
In Specific Aim 1, we will define the viral determinants and associated host pathways responsible for LOT using T1L x T3D-RV reassortant viruses and engineered viral mutants to define functional domains of protein products responsible for LOT. We will elucidate mechanisms underlying IRF1-mediated TH1 immunity following reovirus infection using mice lacking IRF1 or IRF1-inducing factors in specific cell types.
In Specific Aim 2, we will define the effect of T1L and T3D-RV infection on the composition of microbial communities. We will also determine the contribution of the intestinal microbiota to reovirus-induced LOT by assessing LOT in antibiotic-treated and germ-free mice with and without defined microbiota.
In Specific Aim 3, we will define the temporal relationship of T1L infection and gluten introduction on LOT using mice engineered to express the human DQ8 risk allele. We will test whether inoculation with inactivated or attenuated reovirus prior to gluten introduction prevents LOT mediated by T1L. This project extends a productive collaboration of internationally recognized PIs with complementary expertise in CD, mucosal immunology, and virology. Knowledge gained through these efforts will enhance an understanding of how viral infections lead to the development of gastrointestinal inflammatory disorders and foster new strategies to prevent CD in genetically vulnerable individuals.

Public Health Relevance

Celiac disease is a gluten-induced inflammatory disorder of the small intestine for which no non-dietary therapy exists at present. 45% of the U.S. population carries the disease predisposing DQ2 or DQ8 allele, yet < 1% of the population develops the disease, suggesting a role for environmental triggers other than gluten. Loss of oral tolerance to gluten is required for development of celiac disease, and our recent study has demonstrated that reovirus infection triggers development of celiac disease. We seek to advance our understanding of how viruses induces loss of oral tolerance to dietary antigens and to define strategies to prevent virus-induced loss of oral tolerance to gluten and celiac disease development.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
2R01DK098435-05A1
Application #
9826193
Study Section
Gastrointestinal Mucosal Pathobiology Study Section (GMPB)
Program Officer
Hamilton, Frank A
Project Start
2014-05-20
Project End
2023-04-30
Budget Start
2019-07-03
Budget End
2020-04-30
Support Year
5
Fiscal Year
2019
Total Cost
Indirect Cost
Name
University of Chicago
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
005421136
City
Chicago
State
IL
Country
United States
Zip Code
60637
Brown, Judy J; Jabri, Bana; Dermody, Terence S (2018) A viral trigger for celiac disease. PLoS Pathog 14:e1007181
Bouziat, Romain; Biering, Scott B; Kouame, Elaine et al. (2018) Murine Norovirus Infection Induces TH1 Inflammatory Responses to Dietary Antigens. Cell Host Microbe 24:677-688.e5
Mayassi, Toufic; Jabri, Bana (2018) Human intraepithelial lymphocytes. Mucosal Immunol 11:1281-1289
Brown, Judy J; Short, Sarah P; Stencel-Baerenwald, Jennifer et al. (2018) Reovirus-Induced Apoptosis in the Intestine Limits Establishment of Enteric Infection. J Virol 92:
Goel, Gautam; King, Tim; Daveson, A James et al. (2017) Epitope-specific immunotherapy targeting CD4-positive T cells in coeliac disease: two randomised, double-blind, placebo-controlled phase 1 studies. Lancet Gastroenterol Hepatol 2:479-493
Jabri, Bana; Sollid, Ludvig M (2017) T Cells in Celiac Disease. J Immunol 198:3005-3014
Bouziat, Romain; Hinterleitner, Reinhard; Brown, Judy J et al. (2017) Reovirus infection triggers inflammatory responses to dietary antigens and development of celiac disease. Science 356:44-50
Jabri, Bana; Abadie, Valérie (2015) IL-15 functions as a danger signal to regulate tissue-resident T cells and tissue destruction. Nat Rev Immunol 15:771-83
Setty, Mala; Discepolo, Valentina; Abadie, Valérie et al. (2015) Distinct and Synergistic Contributions of Epithelial Stress and Adaptive Immunity to Functions of Intraepithelial Killer Cells and Active Celiac Disease. Gastroenterology 149:681-91.e10
Kim, Sangman Michael; Mayassi, Toufic; Jabri, Bana (2015) Innate immunity: actuating the gears of celiac disease pathogenesis. Best Pract Res Clin Gastroenterol 29:425-35

Showing the most recent 10 out of 11 publications